ILT-101

Phase 2Small molecule

IIltoo Pharma

ILT-101 is one of 42 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Immune DysregulationNot yet recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Immune DysregulationPreclinical

Not yet recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Rituxan

Roche

Phase 3

9 3

Medrol

Pfizer

Phase 3

5 4

Olumiant

Eli Lilly

Phase 3

4 5

Stelara

Johnson & Johnson

Phase 3

3 6

Gazyva

Roche

Phase 3

2 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

11 8

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 9

Rayos

RRoxane Laboratories

Phase 3

6 10

Cellcept

Novartis

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalNot yet recruiting

Immune Dysregulation

NCT07697118

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Completed·IIltoo Pharma·Phase 2·NCT02955615·100 enrolled

T1D1 trial

Low-dose IL-2 in Established T1D - The "PROREG" Study

Withdrawn·JJay S. Skyler·Phase 1/2·NCT03243058

Immune Dysregulation1 trial

A Phase I/II Open-label, Non-randomized, Monocentric, Single-arm Study Evaluating the Safety and Efficacy of Induced CD4+ Treg by LV Vector Transduction Expressing the FOXP3 cDNA (FOXP3-T4) in Patients With IPEX Syndrome

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT07697118·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ILT-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ILT-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ILT-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Iltoo Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIltoo Pharma

ILT-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

T1D1 trial

Immune Dysregulation1 trial

References

Drug Info

Quick Facts

Related News